La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
China Medical System Holdings Croissance future
Future contrôle des critères 4/6
China Medical System Holdings devrait augmenter ses bénéfices et son chiffre d'affaires de 22.5% et de 15.6% par an respectivement. Le BPA devrait croître de de 23% par an. Le rendement des capitaux propres devrait être 15.8% dans 3 ans.
Informations clés
22.5%
Taux de croissance des bénéfices
23.0%
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 11.5% |
| Taux de croissance des recettes | 15.6% |
| Rendement futur des capitaux propres | 15.8% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 19 Aug 2024 |
Mises à jour récentes de la croissance future
Recent updates
Little Excitement Around China Medical System Holdings Limited's (HKG:867) Earnings
Jul 15
An Intrinsic Calculation For China Medical System Holdings Limited (HKG:867) Suggests It's 20% Undervalued
May 22China Medical System Holdings (HKG:867) Is Paying Out Less In Dividends Than Last Year
May 03We Think Shareholders May Want To Consider A Review Of China Medical System Holdings Limited's (HKG:867) CEO Compensation Package
May 02China Medical System Holdings' (HKG:867) Shareholders Will Receive A Smaller Dividend Than Last Year
Apr 19China Medical System Holdings (HKG:867) Is Paying Out Less In Dividends Than Last Year
Mar 29Not Many Are Piling Into China Medical System Holdings Limited (HKG:867) Stock Yet As It Plummets 35%
Mar 28China Medical System Holdings Limited's (HKG:867) Share Price Not Quite Adding Up
Dec 21Is China Medical System Holdings (HKG:867) A Risky Investment?
Dec 04If EPS Growth Is Important To You, China Medical System Holdings (HKG:867) Presents An Opportunity
Nov 15China Medical System Holdings (HKG:867) Will Pay A Larger Dividend Than Last Year At CN¥0.342
Aug 31China Medical System Holdings (HKG:867) Could Easily Take On More Debt
Aug 30Here's Why We Think China Medical System Holdings (HKG:867) Might Deserve Your Attention Today
Aug 07We Think China Medical System Holdings (HKG:867) Can Manage Its Debt With Ease
May 14Does China Medical System Holdings (HKG:867) Deserve A Spot On Your Watchlist?
Apr 26An Intrinsic Calculation For China Medical System Holdings Limited (HKG:867) Suggests It's 47% Undervalued
Feb 05China Medical System Holdings (HKG:867) Seems To Use Debt Rather Sparingly
Dec 26If EPS Growth Is Important To You, China Medical System Holdings (HKG:867) Presents An Opportunity
Dec 08Is China Medical System Holdings (HKG:867) Using Too Much Debt?
Sep 14China Medical System Holdings (HKG:867) Is Paying Out A Larger Dividend Than Last Year
Aug 25Do China Medical System Holdings' (HKG:867) Earnings Warrant Your Attention?
Aug 15An Intrinsic Calculation For China Medical System Holdings Limited (HKG:867) Suggests It's 49% Undervalued
Jul 08Should You Be Adding China Medical System Holdings (HKG:867) To Your Watchlist Today?
May 16Does China Medical System Holdings (HKG:867) Have A Healthy Balance Sheet?
Apr 10China Medical System Holdings (HKG:867) Is Increasing Its Dividend To HK$0.28
Mar 22If You Like EPS Growth Then Check Out China Medical System Holdings (HKG:867) Before It's Too Late
Feb 09Does China Medical System Holdings (HKG:867) Have A Healthy Balance Sheet?
Dec 25Should You Be Adding China Medical System Holdings (HKG:867) To Your Watchlist Today?
Nov 10China Medical System Holdings (HKG:867) Could Easily Take On More Debt
Sep 25China Medical System Holdings' (HKG:867) Dividend Will Be Increased To HK$0.32
Aug 26Here's Why We Think China Medical System Holdings (HKG:867) Is Well Worth Watching
Jul 30An Intrinsic Calculation For China Medical System Holdings Limited (HKG:867) Suggests It's 33% Undervalued
Jun 27China Medical System Holdings (HKG:867) Could Easily Take On More Debt
Jun 14Does China Medical System Holdings (HKG:867) Deserve A Spot On Your Watchlist?
Apr 20Is There An Opportunity With China Medical System Holdings Limited's (HKG:867) 43% Undervaluation?
Mar 25Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 10,710 | 2,626 | 2,761 | N/A | 7 |
| 12/31/2025 | 9,092 | 2,032 | 2,036 | N/A | 9 |
| 12/31/2024 | 7,863 | 1,743 | 1,986 | N/A | 8 |
| 6/30/2024 | 7,014 | 1,390 | N/A | N/A | N/A |
| 3/31/2024 | 7,514 | 1,896 | N/A | N/A | N/A |
| 12/31/2023 | 8,013 | 2,401 | 2,200 | 2,503 | N/A |
| 9/30/2023 | 8,663 | 2,891 | 2,615 | 3,047 | N/A |
| 6/30/2023 | 9,313 | 3,381 | 3,031 | 3,592 | N/A |
| 3/31/2023 | 9,232 | 3,320 | 3,029 | 3,573 | N/A |
| 12/31/2022 | 9,150 | 3,259 | 3,028 | 3,553 | N/A |
| 9/30/2022 | 9,046 | 3,224 | 2,698 | 3,032 | N/A |
| 6/30/2022 | 8,942 | 3,189 | 2,367 | 2,511 | N/A |
| 3/31/2022 | 8,640 | 3,103 | 2,338 | 2,502 | N/A |
| 12/31/2021 | 8,337 | 3,017 | 2,309 | 2,494 | N/A |
| 9/30/2021 | 8,009 | 2,948 | 2,373 | 2,591 | N/A |
| 6/30/2021 | 7,681 | 2,878 | 2,437 | 2,688 | N/A |
| 3/31/2021 | 7,313 | 2,704 | 2,394 | 2,690 | N/A |
| 12/31/2020 | 6,946 | 2,530 | 2,351 | 2,692 | N/A |
| 9/30/2020 | 6,582 | 2,300 | 2,286 | 2,661 | N/A |
| 6/30/2020 | 6,217 | 2,070 | 2,222 | 2,631 | N/A |
| 3/31/2020 | 6,145 | 2,015 | 2,218 | 2,593 | N/A |
| 12/31/2019 | 6,074 | 1,961 | 2,215 | 2,555 | N/A |
| 9/30/2019 | 5,908 | 2,011 | 2,087 | 2,344 | N/A |
| 6/30/2019 | 5,743 | 2,062 | 1,960 | 2,132 | N/A |
| 3/31/2019 | 5,588 | 1,956 | 1,829 | 1,943 | N/A |
| 12/31/2018 | 5,433 | 1,850 | 1,698 | 1,755 | N/A |
| 9/30/2018 | 5,375 | 1,839 | 1,813 | 1,875 | N/A |
| 6/30/2018 | 5,317 | 1,827 | 1,928 | 1,996 | N/A |
| 3/31/2018 | 5,333 | 1,751 | N/A | 2,034 | N/A |
| 12/31/2017 | 5,349 | 1,675 | N/A | 2,072 | N/A |
| 9/30/2017 | 5,379 | 1,601 | N/A | 1,876 | N/A |
| 6/30/2017 | 5,410 | 1,527 | N/A | 1,679 | N/A |
| 3/31/2017 | 5,155 | 1,452 | N/A | 1,421 | N/A |
| 12/31/2016 | 4,901 | 1,376 | N/A | 1,162 | N/A |
| 9/30/2016 | 4,477 | 1,265 | N/A | 1,134 | N/A |
| 6/30/2016 | 4,054 | 1,155 | N/A | 1,105 | N/A |
| 3/31/2016 | 3,804 | 1,075 | N/A | 860 | N/A |
| 12/31/2015 | 3,553 | 996 | N/A | 615 | N/A |
| 9/30/2015 | 3,404 | 1,062 | N/A | 528 | N/A |
| 6/30/2015 | 3,255 | 1,128 | N/A | 441 | N/A |
| 3/31/2015 | 3,100 | 1,087 | N/A | 642 | N/A |
| 12/31/2014 | 2,945 | 1,046 | N/A | 843 | N/A |
| 9/30/2014 | 2,760 | 890 | N/A | 689 | N/A |
| 6/30/2014 | 2,575 | 734 | N/A | 535 | N/A |
| 3/31/2014 | 2,412 | 685 | N/A | 435 | N/A |
| 12/31/2013 | 2,249 | 636 | N/A | 335 | N/A |
| 9/30/2013 | 2,081 | 603 | N/A | 417 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de 867 ( 22.5% par an) est supérieure au taux d'épargne ( 2.3% ).
Bénéfices vs marché: Les bénéfices de 867 ( 21.9% par an) devraient croître plus rapidement que le marché Hong Kong ( 11% par an).
Croissance élevée des bénéfices: Les bénéfices de 867 devraient augmenter de manière significative au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de 867 ( 15.6% par an) devrait croître plus rapidement que le marché Hong Kong ( 7.4% par an).
Croissance élevée des revenus: Le chiffre d'affaires de 867 ( 15.6% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de 867 devrait être faible dans 3 ans ( 15.8 %).